We participate in marketing programs, our editorial content is not influenced by any commissions. To find out more, please visit our Term and Conditions page.
We participate in marketing programs, our editorial content is not influenced by any commissions. To find out more, please visit our Term and Conditions page.
Parataxis on Friday announced that it has invested $18.5 million to acquire a controlling interest in Korean firm Bridge Biotherapeutics, Inc. The acquisition will...